Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rivaroxaban × Myeloid × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 20 Gastrointestinal 3 Tumor-Agnostic 2 Thoracic 2 Plasma cell 2 Genitourinary 2 Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gynecologic 1 CNS 1 Breast 1

Conditions

Myeloproliferative Disorders 1

Interventions

Cyclophosphamide 233 fludarabine phosphate 207 Azacitidine 166 fludarabine 161 Busulfan 150 Imatinib Mesylate 140 Cytarabine 137 Mycophenolic Acid 129 Whole-Body Irradiation 124 Tacrolimus 119 Peripheral Blood Stem Cell Transplantation 118 Melphalan 98 Cyclosporine 98 Antilymphocyte Serum 95 Decitabine 90 Filgrastim 89 Methotrexate 87 nilotinib 83 ruxolitinib 71 venetoclax 69 Dasatinib 59 Stem Cell Transplantation 56 Granulocyte Colony-Stimulating Factor 56 Radiotherapy 54 Thiotepa 52 thymoglobulin 51 Etoposide 44 Specimen Handling 42 Cord Blood Stem Cell Transplantation 39 Clofarabine 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04192916 2021-02-21

MPN-DOACs

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡